prikaz prve stranice dokumenta Protutumorski lijekovi - inhibitori histonske deacetilaze kao epigenetički regulatori u procesu razvoja tumora
  Download
PDF 488.53 KB
undergraduate thesis
Protutumorski lijekovi - inhibitori histonske deacetilaze kao epigenetički regulatori u procesu razvoja tumora
Zagreb: University of Zagreb, Faculty of Food Technology and Biotechnology, 2021. urn:nbn:hr:159:668382
Colar Zanjko, Laura
University of Zagreb
Faculty of Food Technology and Biotechnology
Department of Biochemical Engineering
Laboratory for Antibiotic, Enzyme, Probiotic and Starter Cultures Technology

Institutional repository: Repository of the Faculty of Food Technology and Biotechnology

Cite this document

Colar Zanjko, L. (2021). Protutumorski lijekovi - inhibitori histonske deacetilaze kao epigenetički regulatori u procesu razvoja tumora (Undergraduate thesis). Zagreb: University of Zagreb, Faculty of Food Technology and Biotechnology. Retrieved from https://urn.nsk.hr/urn:nbn:hr:159:668382

Colar Zanjko, Laura. "Protutumorski lijekovi - inhibitori histonske deacetilaze kao epigenetički regulatori u procesu razvoja tumora." Undergraduate thesis, University of Zagreb, Faculty of Food Technology and Biotechnology, 2021. https://urn.nsk.hr/urn:nbn:hr:159:668382

Colar Zanjko, Laura. "Protutumorski lijekovi - inhibitori histonske deacetilaze kao epigenetički regulatori u procesu razvoja tumora." Undergraduate thesis, University of Zagreb, Faculty of Food Technology and Biotechnology, 2021. https://urn.nsk.hr/urn:nbn:hr:159:668382

Colar Zanjko, L. (2021). 'Protutumorski lijekovi - inhibitori histonske deacetilaze kao epigenetički regulatori u procesu razvoja tumora', Undergraduate thesis, University of Zagreb, Faculty of Food Technology and Biotechnology, accessed 29 November 2024, https://urn.nsk.hr/urn:nbn:hr:159:668382

Colar Zanjko L. Protutumorski lijekovi - inhibitori histonske deacetilaze kao epigenetički regulatori u procesu razvoja tumora [Undergraduate thesis]. Zagreb: University of Zagreb, Faculty of Food Technology and Biotechnology; 2021 [cited 2024 November 29] Available at: https://urn.nsk.hr/urn:nbn:hr:159:668382

L. Colar Zanjko, "Protutumorski lijekovi - inhibitori histonske deacetilaze kao epigenetički regulatori u procesu razvoja tumora", Undergraduate thesis, University of Zagreb, Faculty of Food Technology and Biotechnology, Zagreb, 2021. Available at: https://urn.nsk.hr/urn:nbn:hr:159:668382

Metadata
TitleProtutumorski lijekovi - inhibitori histonske deacetilaze kao epigenetički regulatori u procesu razvoja tumora
Title (english)Antitumor drugs - histone deacetylase inhibitors as epigenetic regulators in the process of tumor development
AuthorLaura Colar Zanjko
MentorBlaženka Kos (mentor)
GranterUniversity of Zagreb
Faculty of Food Technology and Biotechnology
(Department of Biochemical Engineering)
(Laboratory for Antibiotic, Enzyme, Probiotic and Starter Cultures Technology)
Zagreb
Defense date and country2021-09-16, Croatia
Scientific / art field,
discipline and subdiscipline		BIOTECHNICAL SCIENCES
Biotechnology
Abstract
Epigenetičke modifikacije, uključujući acetilaciju, metilaciju, fosforilaciju i ubikvitinaciju, igraju ključnu ulogu u regulaciji ekspresije gena. Među enzimima uključenim u epigenetičke modifikacije, histonska deacetilaza (HDAC) potiče relaksaciju kromatina te transkripciju gena. Nekoliko HDAC izoenzima je prekomjerno eksprimirano u različitim malignim bolestima i njihova inhibicija je pristup koji se koristi u razvoju novih protutumorskih lijekova. Na temelju toga provode se klinička istraživanja inhibitora HDAC te su do sada četiri lijeka odobrena od FDA (vorinostat, romidepsin, belinostat i panobinostat). Dokazano je da inhibitori HDAC izazivaju pogrešno savijanje i agregaciju proteina, no mehanizmi njihovog djelovanja nisu u potpunosti istraženi. Pretpostavlja se da mijenjaju način acetilacije citoplazmatskih proteina, što pridonosi njihovom protutumorskom potencijalu. Nedavna istraživanja su dokazala da su sustavi kontrole kvalitete proteina uključeni u prepoznavanje modificiranog načina acetilacije nakon liječenja s inhibitorima HDAC.
Abstract (english)
Epigenetic modifications, including acetylation, methylation, phosphorylation, and ubiquitination, play a key role in regulating gene expression. Among the enzymes involved in epigenetic modifications, histone deacetylase (HDAC) promotes chromatin relaxation and gene transcription. Several HDAC isoenzymes are overexpressed in various malignancies and their inhibition is an approach used in the development of new antitumor drugs. Based on this, clinical trials of HDAC inhibitors are being conducted and so far four drugs have been approved by the FDA (vorinostat, romidepsin, belinostat and panobinostat). HDAC inhibitors have been shown to cause protein misfolding and aggregation, but their mechanisms of action have not been fully investigated. They are thought to alter the way acetylation of cytoplasmic proteins occurs, contributing to their antitumor potential. Recent research has shown that protein quality control systems are involved in recognizing a modified mode of acetylation after treatment with HDAC inhibitors.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:159:668382
Study programmeTitle: Biotechnology
Study programme type: university
Study level: undergraduate
Academic / professional title: sveučilišni/a prvostupnik/prvostupnica (baccalaureus/baccalaurea) inženjer/inženjerka biotehnologije (sveučilišni/a prvostupnik/prvostupnica (baccalaureus/baccalaurea) inženjer/inženjerka biotehnologije)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence Attribution-NoDerivatives 4.0 International (CC BY-ND 4.0) icon
Created on2021-09-29 09:24:14